Leerink Partnrs Has Bearish Outlook for GPCR FY2025 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR) – Equities researchers at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Structure Therapeutics in a research report issued on Tuesday, December 3rd. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $1.94 for the year, down from their prior forecast of $2.04. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.80) per share.

A number of other brokerages have also recently issued reports on GPCR. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. JMP Securities lowered their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Finally, HC Wainwright began coverage on Structure Therapeutics in a report on Wednesday. They issued a “buy” rating and a $80.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $85.67.

Structure Therapeutics Stock Down 6.9 %

NASDAQ:GPCR opened at $31.24 on Thursday. The company has a market capitalization of $1.79 billion, a PE ratio of -42.22 and a beta of -3.41. Structure Therapeutics has a 52-week low of $26.61 and a 52-week high of $63.30. The stock has a fifty day simple moving average of $37.46 and a 200-day simple moving average of $39.32.

Institutional Investors Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in GPCR. Teachers Retirement System of The State of Kentucky boosted its stake in Structure Therapeutics by 17.8% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock worth $589,000 after buying an additional 2,077 shares during the last quarter. Mather Group LLC. acquired a new stake in shares of Structure Therapeutics in the second quarter worth approximately $214,000. Principal Financial Group Inc. purchased a new stake in Structure Therapeutics in the second quarter valued at approximately $6,489,000. Natixis Advisors LLC increased its position in Structure Therapeutics by 29.4% during the second quarter. Natixis Advisors LLC now owns 19,005 shares of the company’s stock worth $746,000 after purchasing an additional 4,321 shares during the last quarter. Finally, Gilbert & Cook Inc. purchased a new position in Structure Therapeutics during the second quarter worth approximately $229,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.